Search
In a proof-of-concept study, researchers at MSK and the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses routine clinical data, such as that from a simple blood test, to predict whether someone’s cancer will respond to immune checkpoint inhibitors, a type of immunotherapy drug that helps immune cells kill cancer cells.
The research identifies a protein called ENPP1 as a potential drug target in the treatment of advanced cancers with chromosome instability.
On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.
With notable cases of pancreatic cancer in the news this year, MSK held an Information Session for Patients and Caregivers with the goal of helping people understand the disease and sharing some of the encouraging breakthroughs in research and treatment.
Memorial Sloan Kettering Cancer Center (MSK) has welcomed Whitney Snider, MD, MBA, as the inaugural Managing Partner of MSK Ventures – a dedicated investment pool that will raise and direct funds to high-growth, early-stage startups created and/or nurtured by MSK faculty and staff.
A $10 million commitment from James H. and Marilyn H. Simons through the Simons Foundation will support preclinical initiatives undertaken as part of Memorial Sloan Kettering's new Brain Tumor Center (BTC).
After two studies examined the safety of eliminating axillary lymph node dissection (ALND) for some breast cancer patients, Memorial Sloan Kettering Cancer Center further tested their conclusions, confirmed the approach’s applicability and changed clinical practice.
Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at MSK, has been awarded the Pasteur-Weizmann/Servier International Prize. Dr. Sadelain was chosen in recognition of his pivotal research demonstrating the therapeutic potential of engineered T cells.
The Ralph Lauren Corporate Foundation announced today that it's providing $25 million in new grant funding to expand or establish five Ralph Lauren cancer centers, aimed at reducing disparities in cancer care and access across underserved communities. The funding will benefit institutions including the Memorial Sloan Kettering (MSK) Ralph Lauren Center in Harlem.
An annual report from an influential cancer group highlights three MSK studies that have advanced cancer research.